Request Processed

Your registration request has been processed. We will contact you soon.

Register

PrevisionPolicy logo
  • Login
  • Register
  • About
  • Contact Us
« First ‹ Prev … 279 280 281 282 283 284 285 286 287 … Next › Last »

The User's Guide to PDUFA V (PDF Attached)

September 7, 2012

GDUFA and BSUFA: Congressional Appropriations Must Kick In For Programs To Start

September 6, 2012

Novartis Tobi Inhaler Wins Advisory Committee Support; Skeptical FDA Review Still An Issue

September 5, 2012

Pediatric Provisions in FDASIA Maintain and Add Incentives, But More Requirements and Timelines Too

September 4, 2012

Split Up HHS? As 2014 Approaches, HHS May Be Too Big To Manage

September 1, 2012

FDA and AIDS: An Overview -- Slide Presentation

September 1, 2012

Novartis Tobi Powder Inhaler Faces Skeptical FDA Review At Upcoming Advisory Committee Review

August 31, 2012

Advisory Committee Tracker: Rare Disease Applications Featured On FDA’s Fall Agenda

August 30, 2012

Teva’s Neupogen-like Product Approved By FDA Goes Through Full BLA, Not Biosimilar Route

August 30, 2012

FDA Advisory Committee Votes for Approval of Abbott’s Humira for Ulcerative Colitis

August 28, 2012

CMS MEDCAC To Reconsider Coverage of Alzheimer’s PET Tracing Agents

August 27, 2012

AIDS Drug Assistance Programs and Health Care Reform: 2013 Will be a Critical Year

August 27, 2012

Abbott’s Humira for Ulcerative Colitis: Additional Trials Pre-Approval a Possibility

August 24, 2012

FDA Publishes Details on Withdrawing Generic Backlog Applications, Two GDUFA Guidance Documents

August 22, 2012

Get Ready for GDUFA: The New Rules for Generic Drug Reviews

August 21, 2012

PDUFA V: Holding the Line on Fees

August 20, 2012

Biosimilars User Fee Act: Up-Front Cost To Sponsors Will Be $200,000 Per IND In FY 2013

August 16, 2012

FDA Inspection Resources and Authority Enhanced By FDASIA

August 14, 2012

GW Obesity Outcomes Paper Points To New Ways To Prove Efficacy; Model For Patient-Centered Regulatory Efforts At FDA

August 14, 2012

Biosimilars Update: Early Analytics the Focus at FDA Pharmaceutical Science Advisory Committee Meeting

August 9, 2012

Qsymia Certified Pharmacy Network Adds Protections Against Generic Regimens

August 8, 2012

REMS in FDASIA: Making Modifications Less Burdensome for Sponsors and REMS Less Burdensome for the Delivery System

July 31, 2012

Senate Hearing On Gray Market Shows Issues Aren’t Black-and-White; Continues Momentum for Track-and-Trace

July 27, 2012

Advisory Committee Votes In Favor of ThromboGenics’ Jetrea for VMA

July 27, 2012

Genentech Lucentis Diabetic Macular Edema Use Headed for Approval: Packaging For Doses, Indications May Delay Action

July 27, 2012
« First ‹ Prev … 279 280 281 282 283 284 285 286 287 … Next › Last »

Patient-Focused
Drug Development
Database

Access database reports on PFDD meetings.

Log In
LEARN MORE
PrevisionPolicy logo sailboat

What is Prevision Policy?

Prevision Policy provides breaking analysis for biopharma on drug regulation, policy and market access. Our continuous information service gives decision makers actionable insight when they need it most on FDA, CMS, Congress, and how developments in policy impact commercial success.

Prevision Policy was started with the belief that information must be trustworthy, interactive, fast as it is deep, and deliver the bottom line. Strategy is developed in real-time and the biopharma business landscape can change quickly and without warning. Our service has been developed to address those challenges and turn them into opportunities.

To request more information about a company license to the Prevision Policy continuous information service or to get further details about the services we offer, please click here.

Biopharma Congress

Copyright © 2026 Prevision Policy. All Rights Reserved. Privacy Policy